Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS (Voclosporin) For Adults with Active Lupus Nephritis (Businesswire) - May 3, 2023 - "Aurinia Pharmaceuticals Inc...announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including mixed class III/V and IV/V)1, when provided in combination with mycophenolate mofetil (MMF). The NICE recommendation applies to England and Wales and follows the recent Medicines and Healthcare Products Regulatory Agency (MHRA) authorization of voclosporin licensed in Great Britain for the treatment of active LN in adult patients....The NICE appraisal is based on the positive results from the pivotal Phase 3 AURORA-1 study and the AURORA-2 continuation study..."
NICE • Immunology • Lupus • Lupus Nephritis • Systemic Lupus Erythematosus
|